Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
JunD CRISPR/Cas9 KO Plasmid (h): sc-400713
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- JunD CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the JunD genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: JunD Antibody (D-9): sc-271938
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
JunD CRISPR/Cas9 KO Plasmid (h) | sc-400713 | 20 µg | $397.00 |
Overview
JUND encodes JunD, a basic leucine zipper transcription factor in the AP-1 family that dimerizes with JUN and FOS proteins to regulate stimulus-responsive gene expression. JunD integrates MAPK signaling and inflammatory cues to control cell-cycle progression, differentiation, oxidative stress responses, and apoptosis through transcriptional modulation of promoters and enhancers. It contributes to chromatin and transcriptional programs downstream of cytokines and growth factors, influencing processes such as extracellular matrix remodeling and immune signaling. Dysregulated AP-1 activity involving JunD has been associated with altered proliferation, stress adaptation, and tumor-related phenotypes in multiple tissue contexts, supporting its relevance for mechanistic disease studies.
JunD CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the JUND gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the JUND together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the JUND open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish JunD protein expression.
This CRISPR knockout system enables efficient generation of JUND-deficient cell models for investigation of JunD signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting JUND exon(s) critical for JunD function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple JUND genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by JunD CRISPR/Cas9 KO Plasmid (h) and JunD CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the JUND locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by JunD HDR Plasmid (h) and JunD HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by JUND homology arms to support homology-directed repair at defined JUND target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.